home  |  investor relations  |  contact us
 biogen idec
portrait_023.jpg

TYSABRI® (natalizumab) Information Center

Recent News About TYSABRI®

FORM 8-K Regarding Other Events (7/31/2008)

Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI® for the Treatment of Multiple Sclerosis (7/22/2008)

Letter to the MS Community (4/17/2008)

Data presented at the 60th Annual Meeting of the AAN Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI® Removal (4/16/2008)

Biogen Idec and Elan Present New TYSABRI® Data at the 60th Annual American Academy of Neurology (4/15/2008)

FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn's Disease (1/14/2008)

Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI® in Patients with Multiple Sclerosis (1/7/2008)

CHMP Adopts Negative Opinion on Appeal on European Application for Natalizumab for The Treatment of Crohn's Disease (11/16/2007)

Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI® for Crohn's Disease (10/15/2007)

New TYSABRI® Data to be Presented at the European Committee for Treatment and Research in MS (10/11/2007)

Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI® in Patients with MS (10/11/2007)

TYSABRI® Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology (8/20/2007)

Joint FDA Advisory Committee Recommends Approval of TYSABRI® for the Treatment of Moderate to Severe Crohn's Disease (7/31/2007)

TYSABRI® Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis (7/23/2007)

Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease (7/19/2007)

Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI® for the Treatment of Crohn's Disease (5/29/2007)

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI® in Patients with Multiple Sclerosis (5/3/2007)


2006 News Archive

2005 News Archive



  

Biogen Idec MS Support Specialists available at 1-800 456-2255

Commitment to Those
We Serve

Learn more about Biogen Idec's
Core Values...
   
 

The information set forth in the Biogen Idec documents posted on this page was factually accurate
on the date it was issued. While this information remains on Biogen Idec's website, the company
assumes no duty to update the information to reflect subsequent developments. Consequently, readers
of this information should not rely on it as current or accurate after the issuance dates
© Biogen Idec | Terms and Conditions of Use | Note Regarding Forward-Looking Statements | Privacy Policy